<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01667341</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-003-001</org_study_id>
    <nct_id>NCT01667341</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine</brief_title>
  <official_title>A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genocea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genocea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, dose escalation study. There will be 3 cohorts
      of patients defined by the antigen dose (10, 30 or 100 µg of each antigen), and within each
      cohort, patients will be randomized at a ratio of 3:1:1 to one of the following:

        1. GEN-003/M2: GEN-003 plus Matrix M-2 adjuvant (50 µg per dose)

        2. GEN-003: Antigens alone

        3. Placebo (DPBS diluent)

      Each Cohort is divided into 2 Groups. For each dose cohort, immunizations begin with a Pilot
      Group. Immunization of the remainder of the Group &quot;Continuation Group&quot;) is contingent upon
      successful review of data from the Pilot Group through Day 7 after immunization. Dose
      escalation to the next dose level Cohort proceeds after evaluation of safety data from all
      patients in the prior Cohort and only after all specified safety criteria are met. The total
      numbers of patients in each Group and Cohort are as follows:

        -  10 µg Cohort: 10 Pilot Group, 40 Continuation Group (50 Total)

        -  30 µg Cohort: 10 Pilot Group, 40 Continuation Group (50 Total)

        -  100 µg Cohort: 10 Pilot Group, 40 Continuation Group (50 Total)

        -  Totals per group: 30 Pilot Group, 120 Continuation Group (150 Total Patients)

      Subjects will receive 3 doses of the assigned treatment (GEN-003/M-2, GEN-003, or placebo) at
      3 week intervals. Sampling from mucocutaneous genital sites for viral shedding will be done
      twice daily for 28 days prior to the first immunization (baseline shedding), and again
      following the last immunization. Follow-up for safety monitoring will be conducted for 12
      months after the last immunization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>57 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measured by humoral (antibody) and T-cell responses to vaccine antigens</measure>
    <time_frame>33 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of days with detectable viral shedding</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Genital Herpes Simplex Type 2</condition>
  <arm_group>
    <arm_group_label>Low Dose GEN-003 with Matrix M-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10µg GEN-003, 50µg Matrix M-2 Adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose GEN-003 with Matrix M-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30µg GEN-003, 50µg Matrix M-2 Adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose GEN-003 with Matrix M-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100µg GEN-003, 50µg Matrix M-2 Adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose GEN-003 Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10µg GEN-003</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose GEN-003 Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30µg GEN-003</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose GEN-003 Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100µg GEN-003</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5 mL phosphate buffered saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-003 with Matrix M-2</intervention_name>
    <description>IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.</description>
    <arm_group_label>Low Dose GEN-003 with Matrix M-2</arm_group_label>
    <arm_group_label>Mid Dose GEN-003 with Matrix M-2</arm_group_label>
    <arm_group_label>High Dose GEN-003 with Matrix M-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-003</intervention_name>
    <description>IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).</description>
    <arm_group_label>Low Dose GEN-003 Only</arm_group_label>
    <arm_group_label>Mid Dose GEN-003 Only</arm_group_label>
    <arm_group_label>High Dose GEN-003 Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBS</other_name>
    <other_name>DPBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18 to 50 years, inclusive.

          -  Willing to practice a highly effective method of contraception that includes the use
             of a barrier method such as a condom.

          -  Diagnosis of genital HSV-2 infection for &gt; 1 year supported by ONE of the following
             documented in the medical history or performed at screening:

               -  Western blot for HSV-2

               -  Type-specific polymerase chain reaction (PCR) or viral culture

               -  Compatible clinical history AND HSV-2 ELISA (HerpSelect) index value &gt;3.5

          -  A history of at least 3 and no more than 9 reported clinical occurrences in the prior
             12 months, or, if currently on suppressive therapy, history of at least 3 and no more
             than 9 reported clinical occurrences in the 12 months prior to initiation suppressive
             therapy.

          -  Good general health status as determined by screening evaluation completed within 90
             days prior to immunization. Any out of range screening clinical laboratory values
             should be considered not clinically significant by the Investigator.

          -  Patient has provided written informed consent.

          -  Ability and willingness to perform and comply with all study procedures including
             attending clinic visits as scheduled. Note: patients must provide, by the day of
             randomization, a minimum of 28 (equivalent of 14 days) baseline viral swab samples to
             continue to be eligible and be randomized).

        Exclusion Criteria:

          -  On suppressive antiviral medication within 7 days of baseline viral shedding
             evaluation.

          -  Immunocompromised individuals, including those receiving systemic corticosteroids or
             other immunosuppressive agents.

          -  Positive serologic test for HIV-1 infection; positive hepatitis B surface antigen
             (HBsAg) or antibody for hepatitis C (anti-HCV).

          -  Active lesions consistent with herpetic disease at the time of scheduled immunization.

          -  Pregnant or nursing women.

          -  Receipt of any investigational drug within 30 days of the first scheduled day of
             immunization.

          -  History of hypersensitivity to any component of the vaccine.

          -  History of genital HSV-1 infection.

          -  History of: (1) any form of ocular HSV infection, (2) HSV-related erythema multiforme,
             or (3) herpes meningitis or encephalitis.

          -  Any other condition which in the opinion of the Investigator would interfere with the
             successful completion of the study protocol.

          -  History of drug or alcohol abuse that, in the opinion of the Investigator, would
             interfere with the patient's ability to comply with the requirements of the study.

          -  Prior immunization with a vaccine containing HSV-2 antigens.

          -  Receipt of blood products within 90 days of the first immunization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama Vaccine Research Unit</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Infectious Disease Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westover Heights Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies - Clear Lake/Webster</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <disposition_first_submitted>December 1, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 1, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 30, 2015</disposition_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSV</keyword>
  <keyword>Herpes</keyword>
  <keyword>genital infection</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

